TruSight Pan-Cancer RNA Panel

Overview

The Illumina TruSight Pan-Cancer RNA panel is a targeted RNA sequencing panel designed to detect gene fusions, expression levels, and splice variants across genes frequently altered in cancer. It captures RNA from a curated set of cancer-relevant genes and uses anchored multiplex PCR (AMP) chemistry to enable partner-agnostic fusion detection. The panel is used in clinical and research settings for molecular profiling of solid tumors.

Used by

• Used in retrospective molecular profiling of a urinary bladder small round cell sarcoma; detected an EWSR1::BEND2 in-frame fusion (EWSR1 exon 10 to BEND2 exon 2), subsequently confirmed by Sanger sequencing. This RNA panel approach resolved the fusion partner that EWSR1 break-apart FISH could not identify PMID:28199314

Notes

• Partner-agnostic fusion detection enables identification of novel fusion partners not targeted by break-apart FISH probes.
• Suitable for FFPE and fresh-frozen tumor material.
• Complementary to DNA-based sequencing for structural rearrangement characterization.

Sources

• PMID:28199314

This page was processed by crosslinker on 2026-05-14.